Fort Sheridan Advisors LLC bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 4,924 shares of the exchange traded fund’s stock, valued at approximately $493,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital A Wealth Management LLC bought a new stake in shares of SPDR S&P Biotech ETF in the second quarter valued at about $26,000. Davis Capital Management acquired a new position in shares of SPDR S&P Biotech ETF during the third quarter worth about $35,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of SPDR S&P Biotech ETF during the second quarter worth about $32,000. Johnson Financial Group Inc. bought a new position in shares of SPDR S&P Biotech ETF during the second quarter worth about $31,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new stake in SPDR S&P Biotech ETF in the 3rd quarter valued at approximately $40,000.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $127.12 on Tuesday. The stock has a market capitalization of $8.49 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93. The stock’s 50 day moving average price is $125.25 and its two-hundred day moving average price is $114.38. SPDR S&P Biotech ETF has a 52 week low of $66.66 and a 52 week high of $132.09.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- The Market Just Split in Two (URGENT)
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
